deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02314247

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Multi-center, Phase 2, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE™) Selinexor (KPT-330) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL)

Sponsor: Karyopharm Therapeutics Inc

Conditions Cutaneous T-cell Lymphoma (CTCL) Peripheral T-cell Lymphoma (PTCL)
Interventions Selinexor
Updated 12 times since 2017 Last updated: Jan 24, 2023 Started: Feb 28, 2015 Primary completion: Jan 31, 2016 Completion: Feb 29, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to enrollment challenges

Other terminated trials from Karyopharm Therapeutics Inc

More terminations from Karyopharm Therapeutics Inc

Listed as NCT02314247, this PHASE2 trial focuses on Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL) and remains terminated or withdrawn. Sponsored by Karyopharm Therapeutics Inc, it has been updated 12 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~May 2017 · 3 months · monthly snapshotTerminated~May 2017 – ~Jun 2018 · 13 months · monthly snapshotTerminated~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotTerminated~Sep 2018 – ~Oct 2020 · 25 months · monthly snapshotTerminated~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Feb 2023 · 14 months · monthly snapshotTerminated~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Feb 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Feb 2023 [monthly]

    Terminated PHASE2

▶ Show 7 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Oct 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Sep 2018 — Oct 2020 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Sep 2018 [monthly]

    Terminated PHASE2

  5. May 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  6. Feb 2017 — May 2017 [monthly]

    Terminated PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Karyopharm Therapeutics Inc
Data source: Karyopharm Therapeutics Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations